A vial and sryinge are seen in front of a displayed AstraZeneca logo in this illustration taken January 11, 2021. REUTERS/Dado Ruvic/Illustrationis working as fast as possible to compile data on its COVID-19 vaccine to apply for U.S. approval but the dataset is very big, executives said on Friday as the drugmaker faces delays to its submission.
"There's a lot more data than just a Phase III study and so we're working as fast as we can to pull it all together and submit," said Mene Pangalos, executive vice president of BioPharmaceuticals R&D at AstraZeneca. Chief executive Pascal Soriot said in a briefing following the release of first-quarter results there was nothing wrong with the data, but the dataset was very big.
On Friday, the company said it planned to apply for U.S. approval in the coming weeks. That is a delay from late March when the company also said it would submit the data in the coming weeks.Our Standards:
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Covid:19: Nisra records slight increase in NI Covid deathsCovid-19 was mentioned on the death certificates of eight people in NI up to Friday 30 April.
Source: bbchealth - 🏆 143. / 63 Read more »
Covid-19: Some Covid safeguards needed after June, says RaabBut the foreign secretary says the UK is in a 'good position' for life to be 'close to normal' again. That lovely open ended, unmeasurable, undefined word. ‘Some’.
Source: bbchealth - 🏆 143. / 63 Read more »
WSJ News Exclusive | AstraZeneca Struggles With Data Needed for Covid-19 Vaccine’s ApprovalThe drugmaker is grappling with delays in its efforts to seek U.S. authorization for its shot, with FDA signoff seen as critical to vaccine drives around the world. good Watch
Source: WSJ - 🏆 98. / 63 Read more »
AstraZeneca Q1 COVID-19 vaccine revenue $275 mlnAstraZeneca (AZN.L) said on Friday its COVID-19 vaccine contributed $275 million in sales and shaved off three cents per share from its first-quarter earnings, as the drugmaker reported better-than-expected results and forecast sales growth. 한국의 경기의 퇴조 방송국의선전--주로 보험 의약품등 효용이적거나 과도한 집중처로 치우치는듯--사립 국영방송국은 제구실은 못하지만 상당히 주요위치이지요 어떠한 품목 선전이 좋을 까요? 공부하여 생각해보세요 선전으로 회사에서 돈보태주기 --회사와 돈나름 인듯 What revenue for Pfizer and Moderna ? Why to hyde ? Give full information for your credibility, And do inform of the blood clot cases in brain after AZ doses & how many died...
Source: Reuters - 🏆 2. / 97 Read more »
Argentina pushes AstraZeneca on COVID-19 vaccine supply amid holdupsArgentina's government said on Wednesday that it met with representatives of drugmaker AstraZeneca Plc (AZN.L) to ask about 'difficulties' in the production of its COVID-19 vaccine and supply of it to the country. KCC_Not_Working KCC_Not_Working KCC_Not_Working
Source: Reuters - 🏆 2. / 97 Read more »